BMS-986453

Overview

BMS-986453 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize proteins found on myeloma cells more easily. This treatment targets two proteins found on myeloma cells, BCMA and GPRC5D.

SparkCures ID 740
Generic Name BMS-986453
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or R...
BMS-986453
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.